Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
NAMS · NASDAQ · Pharmaceutical Preparations
Newamsterdam Pharma Co N.V. (NAMS) · oqro.io/stocks/NAMS · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$18.41−1.10 (−5.64%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
2 routine filings (option exercises, shares withheld for taxes, grants, gifts) are not listed here. Show them
Insider buying
Traded Sep 15, 2025 · filed 2 days later
A Newamsterdam Pharma director paid $16K out of pocket for Newamsterdam Pharma shares.
Insider buying
Traded Sep 8, 2025 · filed 2 days later
A Newamsterdam Pharma director paid $31K out of pocket for Newamsterdam Pharma shares.
Traded Sep 9, 2025 · largest single transaction ~$2.53MNot reported under a pre-arranged trading plan
Sep 9, 2025~$2.53M · 97K sh @ $26.11
Insider selling
Traded Sep 3, 2025 · filed 2 days laterNot reported under a pre-arranged trading plan
Newamsterdam Pharma's Chief Accounting Officer sold $453K of Newamsterdam Pharma shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
Traded Aug 25, 2025 · filed 2 days laterNot reported under a pre-arranged trading plan
Newamsterdam Pharma's Chief Accounting Officer sold $206K of Newamsterdam Pharma shares. The filing does not indicate a pre-arranged trading plan.
Traded Aug 21 – Aug 22, 2025 · largest single transaction ~$1.21MNot reported under a pre-arranged trading plan
Aug 21, 2025~$1.21M · 50K sh @ $24.29
DetailsInsider buying
Traded Aug 11, 2025 · filed 2 days later
A Newamsterdam Pharma director paid $11K out of pocket for Newamsterdam Pharma shares.
Douglas F Kling (Chief Operating Officer) sold ~$1.08M of Newamsterdam Pharma Co N.V.
Planned saleDouglas F Kling (Chief Operating Officer) sold ~$941K of Newamsterdam Pharma Co N.V.
Planned saleDouglas F Kling (Chief Operating Officer) sold ~$78K of Newamsterdam Pharma Co N.V.
Planned saleTraded Jun 24 – Jun 25, 2025 · largest single transaction ~$46K
Jun 24, 2025~$46K · 2,520 sh @ $18.43
DetailsOfficial recordInsider buying
Traded Jun 16, 2025 · filed 2 days later
A Newamsterdam Pharma director paid $167K out of pocket for Newamsterdam Pharma shares.
Douglas F Kling (Chief Operating Officer) sold ~$1.57M of Newamsterdam Pharma Co N.V.
Planned saleDouglas F Kling (Chief Operating Officer) sold ~$358K of Newamsterdam Pharma Co N.V.
Planned saleInsider buying
Traded Mar 26, 2025 · filed 2 days later
A Newamsterdam Pharma director paid $26K out of pocket for Newamsterdam Pharma shares.
Insider buying
Traded Mar 4, 2025 · filed 2 days later
A Newamsterdam Pharma director paid $84K out of pocket for Newamsterdam Pharma shares.
Insider selling
Traded Mar 4, 2025 · filed 1 day laterNot reported under a pre-arranged trading plan
Newamsterdam Pharma's Chief Accounting Officer sold $3.06M of Newamsterdam Pharma shares. The filing does not indicate a pre-arranged trading plan.
ForGrowth NAP B.V. (10% owner) sold ~$762K of Newamsterdam Pharma Co N.V.
Planned saleForGrowth NAP B.V. (10% owner) sold ~$1.08M of Newamsterdam Pharma Co N.V.
Planned saleForGrowth NAP B.V. (10% owner) sold ~$870K of Newamsterdam Pharma Co N.V.
Planned saleForGrowth NAP B.V. (10% owner) sold ~$1.13M of Newamsterdam Pharma Co N.V.
Planned saleForGrowth NAP B.V. (10% owner) sold ~$641K of Newamsterdam Pharma Co N.V.
Planned saleForGrowth NAP B.V. (10% owner) sold ~$415K of Newamsterdam Pharma Co N.V.
Planned saleForGrowth NAP B.V. (10% owner) sold ~$147K of Newamsterdam Pharma Co N.V.
Planned saleForGrowth NAP B.V. (10% owner) sold ~$1.44M of Newamsterdam Pharma Co N.V.
Planned saleForGrowth NAP B.V. (10% owner) sold ~$1.4M of Newamsterdam Pharma Co N.V.
Planned saleForGrowth NAP B.V. (10% owner) sold ~$1.23M of Newamsterdam Pharma Co N.V.
Planned saleForGrowth NAP B.V. (10% owner) sold ~$1.71M of Newamsterdam Pharma Co N.V.
Planned saleForGrowth NAP B.V. (10% owner) sold ~$1.26M of Newamsterdam Pharma Co N.V.
Planned saleForGrowth NAP B.V. (10% owner) sold ~$27K of Newamsterdam Pharma Co N.V.
Planned saleForGrowth NAP B.V. (10% owner) sold ~$3.54M of Newamsterdam Pharma Co N.V.
Planned saleForGrowth NAP B.V. (10% owner) sold ~$680K of Newamsterdam Pharma Co N.V.
Planned saleForGrowth NAP B.V. (10% owner) sold ~$644K of Newamsterdam Pharma Co N.V.
Planned saleForGrowth NAP B.V. (10% owner) sold ~$6.55M of Newamsterdam Pharma Co N.V.
Planned saleForGrowth NAP B.V. (10% owner) sold ~$3.3M of Newamsterdam Pharma Co N.V.
Planned saleSep 9, 2025~$1.34M · 53K sh @ $25.31
DetailsOfficial recordAug 22, 2025~$1.06M · 42K sh @ $25.08
DetailsOfficial recordAug 22, 2025~$195K · 7,658 sh @ $25.49
DetailsOfficial recordJun 25, 2025~$23K · 1,260 sh @ $18.26
DetailsOfficial record0 open-market purchases and 1 open-market sale by insiders of NAMS between Dec 10, 2025 and today, placed against the company's last 4 earnings releases. The latest on file was filed Aug 5, 2026. The data provider lists the next release for Feb 16, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Aug 5, 2026 | None | None | None |
| May 7, 2026 | None | None | None |
| Feb 18, 2026 | None | None | None |
| Jan 9, 2026 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies